Exploring psychedelic experiences among people who regularly use methamphetamine: Findings from an international survey.
Dilara Bahceci, Krista J. Siefried, Maureen Steele, Mary Harrod, Georgina Bell, Monica J Barratt, Christopher R. Nicholas, Anthony Rodgers, Peter S. Hendricks, Christopher S. Stauffer, Paul Liknaitzky, Jonathan Brett
Drug and Alcohol Dependence July 1, 2025 DOI: 10.1016/j.drugalcdep.2025.112699 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Retrospective survey Peer reviewed |
|---|---|
| Sample size | 268 |
| Population | People who used methamphetamine and psychedelics |
| Topics | Addiction Psychedelic-assisted therapy |
| Keywords | Hallucinogens Polysubstance Psychedelics Addiction treatment Methamphetamine dependence Harm reduction Substance abuse recovery |
| Key findings | Psychedelic use among people who use methamphetamine was associated with improved mood, social functioning, and reduced substance use, with planning and less challenging experiences linked to better outcomes. |
Abstract
Methamphetamine use disorder, associated with significant morbidity and mortality, has limited effective treatments. Psychedelic-assisted psychotherapy shows promise, but data on its safety and efficacy in this population are limited. This exploratory study describes the demographic, substance use, and mental health characteristics of people who used methamphetamine and psychedelics and the context and outcomes of their psychedelic experiences. A retrospective survey collected data on demographics, substance use patterns, mental health, and psychedelic use. Binomial logistic regression explored associations of post-psychedelic positive mood and social functioning ('increased'/'not increased') and substance use ('reduced'/'not reduced') with demographics, psychosocial factors, mental health, substance use patterns, and psychedelic use context. Among 268 participants, 48.5 % had a diagnosed mental illness, 45.1 % were at risk of suicide, 61.2 % reported psychotic symptoms, 45.1 % had high-risk methamphetamine use, and 82.1 % had taken substances other than methamphetamine and psychedelics. Most psychedelic experiences were unplanned (52.6 %), recreationally motivated (73 %), and combined with other drugs (52.6 %). Post-experience, participants reported improved mood (59.3 %) and social functioning (49.6 %), and reduced use of methamphetamine (34.0 %) and other substances (35.1 %). Forward planning and less challenging experiences were linked to improved mood (aOR 1.84, p = 0.048; aOR 2.21, p = 0.012) and reduced substance use (aOR 2.27, p = 0.008; aOR 3.58, p < 0.001). Psychedelic use among people who use methamphetamine may improve mood and social function, and reduce substance use. The complex findings highlight the potential importance of psychosocial and environmental factors ("set and setting") in determining outcomes, underscoring the need for controlled clinical trials and tailored harm reduction strategies.
Comparable studies
Other cross-sectional and survey studies on psychedelic-assisted therapy, most cited first.
Citations in the library
Cites 71
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Proceedings of the National Academy of Sciences January 23, 2012
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
and 66 more in the library